|Bid||43.78 x 1400|
|Ask||43.78 x 800|
|Day's Range||43.51 - 43.94|
|52 Week Range||33.20 - 45.81|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||11.04|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.36 (3.13%)|
|1y Target Est||43.79|
Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland.
Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.
Market watchers and analysts are waiting for a tweet from President Trump to try to embarrass or strong arm management into rescinding the raises. The rising On-Balance-Volume (OBV) is positive until early October and then it turns neutral/positive. Prices dip in October/November but the OBV line has been steady/flat telling me that buyers and sellers of PFE have been balanced.
drug price increases that defy the oval office are provoking a mixed response. Shares of the New York City-based pharmaceutical giant have remained largely flat to slightly negative in pre-market, adding further signs of uncertainty to what has been a tumultuous fourth quarter so far amid pressure from both President Trump and HHS Secretary Alex Azar on the pricing issue. The company's announcement of price increases comes shortly after HHS Secretary Azar discussed problems with transparency and pricing controls in the industry.
Bausch Health’s (BHC) wholly owned subsidiary Ortho Dermatologics generated revenues of $177.0 million in the third quarter. In the third quarter, Ortho Dermatologics’ net revenues remained flat compared to the third quarter of 2017. Ortho Dermatologics witnessed ~1% YoY organic revenue growth.
The Zacks Analyst Blog Highlights: Pfizer, Cisco, Southern, SunTrust Banks and AmerisourceBergen
Merck KGaA and Pfizer Inc. said early Monday that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial. The trial, JAVELIN Ovarian 200, tested avelumab both alone and in combination with chemotherapy. It specifically focused on individuals with platinum-resistant or -refractory ovarian cancer, or cancers that did not respond to prior chemotherapy treatment, "a population known to have disease that is challenging to treat; as such, this group of patients in typically not included in Phase 3 ovarian cancer trials," Dr. Chris Boshoff, Pfizer's senior vice president and head of immuno-Oncology, early development and translational oncology, said. "The results speak to the significant challenges these women face." Another Merck and Pfizer trial of avelumab, in a type of lung cancer, also did not meet its primary endpoint earlier this year. The drug is being tested in several other types of cancer, with roughly 17 total clinical trials ongoing, according to Pfizer's drug pipeline. Both U.S.-listed Merck KGaA and Pfizer shares were inactive in Monday premarket trade. Merck KGaA shares have surged 8.8% over the last three months and Pfizer shares have risen 3.4%, compared with a nearly 4% drop in the S&P 500 and a 1% decline in the Dow Jones Industrial Average .
DARMSTADT, Germany and NEW YORK , November 19, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN ...
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Pfizer and Facebook were both in deep water last week. Pharma giant Pfizer decided to increase the prices of 41 drugs according to the WSJ with the price hikes taking effect in January. Shares of Facebook hit a new low as Wall Street continued to grapple with a NY Times article about executives at the company ignoring warning signs of abuse.
shares plunged to the lowest level in four years Monday, wiping more than $2 billion from the company's market value, after Nissan Motor Co. said chairman Carlos Ghosn misused company funds following an investigation in cooperation with Japan's Public Prosecutors Office. The Nissan statement followed a a report from Japan's Asahi newspaper, and other media outlets, that the Renault CEO faces arrest for allegedly violating the country's financial instruments and exchange linked to his role as chairman of Nissan Motor Co.
said Friday, Nov. 16, it plans to increase list prices for 41 of its drugs effective Jan. 15. The plan was first reported by The Wall Street Journal. "The only exceptions are three products that have a 3% increase and one product that is increasing 9% due to the completion of two extensive development programs that have led to the recent FDA approvals of two new medical uses that meet unmet patient needs," Pfizer said.
Pfizer Inc. plans to resume its practice of raising drug prices early next year after bowing to pressure from President Trump over the summer when the company rolled back some increases. Pfizer, among the world’s biggest drugmakers by sales, won’t be raising prices as much as it has in past years. It said it would raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January.
Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the list price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one by 9 percent, all effective Jan. 15. Pfizer said it does not expect the price increases to boost its revenue in the United States next year as it believes that rebates to insurance companies and pharmacy benefit managers (PBMs) will offset them.
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10 percent of its portfolio, in January. According to The Wall Street Journal, citing an unnamed source, most of the planned increases will be 5 percent, while three of the drugs’ list prices will go up by 3 percent. One of the drug prices will go up by 9 percent, the report continued.
Pfizer plans to raise the list prices of 41 of its prescription drugs, or 10% of its portfolio, in January, The Wall Street Journal reported Friday, citing a person familiar with the matter. Most of the increases will be around 5% and would take effect Jan. 15, the person said, according to the WSJ. Pfizer rolled back some increases in July under criticism from President Donald Trump, but earlier this month Chief Executive Ian Read said Pfizer was likely to go back to price hikes in January. Shares of Pfizer rose 0.1% in the extended session Friday after ending the regular trading day up 0.7%.
Pfizer will raise list prices on 41 prescription drugs in January. Pfizer this summer deferred planned price increases after President Donald Trump criticized the drug giant. Trump said Pfizer and other drugmakers "should be ashamed" of themselves.
Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous price increases this summer under pressure from President Donald Trump. Pfizer said it would raise the price of most of the drugs by 5 percent, while prices for three will rise by 3 percent, and the price of one other will rise by 9 percent.
On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.
Pfizer said it would increase the price of 41 products in its drug portfolio, just four months after having initially put off those plans amid heavy criticism from US President Donald Trump. — after Mr Trump said it should be “ashamed” of the move and that it and other rivals were “taking advantage of poor people”. Effective January 15, 2019, prices for 37 of the products will rise by 5 per cent, while three products will see prices rise by 3 per cent, and one by 9 per cent.
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.